Adial Pharmaceuticals announced on August 20, 2025, its encouragement regarding recent U.S. Senate legislative support for expanding clinical trial endpoints in alcohol and substance use disorder treatments. This support includes endpoints beyond traditional abstinence.
The U.S. Senate Appropriations Report further validates Adial’s therapeutic approach, which aligns with a broader, non-abstinence definition of recovery. This promotes a more contemporary and patient-focused regulatory environment.
This development is significant for Adial's AD04 program, which has the potential to offer patients the flexibility of reducing drinking, in addition to abstinence. Such legislative support could facilitate the regulatory pathway for AD04 and its acceptance in the market.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.